Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

In vivo genome editing using Staphylococcus aureus Cas9


The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biochemical screen for small Cas9 orthologues.
Figure 2: Characterization of Staphylococcus aureus Cas9 (SaCas9) in 293FT cells.
Figure 3: Characterization of genome-wide nuclease activity of SaCas9 and SpCas9.
Figure 4: AAV-delivery of SaCas9 for in vivo genome editing.
Figure 5: Liver function tests and toxicity examination in injected animals.

Accession codes

Primary accessions


Data deposits

All reagents described in this manuscript have been deposited with Addgene (plasmid IDs 61591, 61592 and 61593). Source data are available online and deep sequencing data are available at Sequence Read Archive under BioProject accession number PRJNA274149.


  1. Bolotin, A., Quinquis, B., Sorokin, A. & Ehrlich, S. D. Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology 151, 2551–2561 (2005)

    Article  CAS  PubMed  Google Scholar 

  2. Barrangou, R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709–1712 (2007)

    ADS  CAS  PubMed  Google Scholar 

  3. Garneau, J. E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67–71 (2010)

    Article  ADS  CAS  PubMed  Google Scholar 

  4. Deltcheva, E. et al. CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471, 602–607 (2011)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  5. Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Res. 39, 9275–9282 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gasiunas, G., Barrangou, R., Horvath, P. & Siksnys, V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl Acad. Sci. USA 109, E2579–E2586 (2012)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013)

    ADS  CAS  PubMed  PubMed Central  Google Scholar 

  9. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  10. Gaudet, D. et al. Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. Atheroscler. Suppl. 11, 55–60 (2010)

    Article  CAS  PubMed  Google Scholar 

  11. Vasileva, A. & Jessberger, R. Precise hit: adeno-associated virus in gene targeting. Nature Rev. Microbiol. 3, 837–847 (2005)

    Article  CAS  Google Scholar 

  12. Mingozzi, F. & High, K. A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nature Rev. Genet. 12, 341–355 (2011)

    Article  CAS  PubMed  Google Scholar 

  13. Gao, G., Vandenberghe, L. H. & Wilson, J. M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285–297 (2005)

    Article  CAS  PubMed  Google Scholar 

  14. Kay, M. A. State-of-the-art gene-based therapies: the road ahead. Nature Rev. Genet. 12, 316–328 (2011)

    Article  ADS  CAS  PubMed  Google Scholar 

  15. Zincarelli, C., Soltys, S., Rengo, G. & Rabinowitz, J. E. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 16, 1073–1080 (2008)

    Article  CAS  PubMed  Google Scholar 

  16. Swiech, L. et al. In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nature Biotechnol. 33, 102–106 (2015)

    Article  CAS  Google Scholar 

  17. Senís, E. et al. CRISPR/Cas9-mediated genome engineering: an adeno-associated viral (AAV) vector toolbox. Biotechnol. J. 9, 1402–1412 (2014)

    Article  PubMed  Google Scholar 

  18. Nishimasu, H. et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935–949 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Chylinski, K., Makarova, K. S., Charpentier, E. & Koonin, E. V. Classification and evolution of type II CRISPR-Cas systems. Nucleic Acids Res. 42, 6091–6105 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Chylinski, K., Le Rhun, A. & Charpentier, E. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems. RNA Biol. 10, 726–737 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nature Biotechnol. 31, 827–832 (2013)

    Article  CAS  Google Scholar 

  23. Hou, Z. et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl Acad. Sci. USA 110, 15644–15649 (2013)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  24. Fu, Y., Sander, J. D., Reyon, D., Cascio, V. M. & Joung, J. K. Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nature Biotechnol. 32, 279–284 (2014)

    Article  CAS  Google Scholar 

  25. Semenova, E. et al. Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence. Proc. Natl Acad. Sci. USA 108, 10098–10103 (2011)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  26. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnol. 31, 822–826 (2013)

    Article  CAS  Google Scholar 

  27. Mali, P. et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnol. 31, 833–838 (2013)

    Article  CAS  Google Scholar 

  28. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nature Biotechnol. 31, 839–843 (2013)

    Article  CAS  Google Scholar 

  29. Lin, Y. et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Res. 42, 7473–7485 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Bae, S., Park, J. & Kim, J.-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473–1475 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wu, X. et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nature Biotechnol. 32, 670–676 (2014)

    Article  CAS  Google Scholar 

  32. Kuscu, C., Arslan, S., Singh, R., Thorpe, J. & Adli, M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nature Biotechnol. 32, 677–683 (2014)

    Article  CAS  Google Scholar 

  33. Crosetto, N. et al. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing. Nature Methods 10, 361–365 (2013)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Young, S. G. Recent progress in understanding apolipoprotein B. Circulation 82, 1574–1594 (1990)

    Article  CAS  PubMed  Google Scholar 

  35. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004)

    Article  ADS  CAS  PubMed  Google Scholar 

  36. Rozema, D. B. et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl Acad. Sci. USA 104, 12982–12987 (2007)

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  37. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnol. 25, 1149–1157 (2007)

    Article  CAS  Google Scholar 

  38. Fitzgerald, K. et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383, 60–68 (2014)

    Article  CAS  PubMed  Google Scholar 

  39. Abifadel, M. et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nature Genet. 34, 154–156 (2003)

    Article  CAS  PubMed  Google Scholar 

  40. Cohen, J. et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nature Genet. 37, 161–165 (2005)

    Article  CAS  PubMed  Google Scholar 

  41. Horton, J. D., Cohen, J. C. & Hobbs, H. H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32, 71–77 (2007)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Briner, A. E. et al. Guide RNA functional modules direct Cas9 activity and orthogonality. Mol. Cell 56, 333–339 (2014)

    Article  CAS  PubMed  Google Scholar 

  43. Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nature Biotechnol. 33, 187–197 (2015)

    Article  CAS  Google Scholar 

  44. Frock, R. L. et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nature Biotechnol. 33, 179–186 (2015)

    Article  CAS  Google Scholar 

  45. Crooks, G. E., Hon, G., Chandonia, J.-M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188–1190 (2004)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Gautheret, D. & Lambert, A. Direct RNA motif definition and identification from multiple sequence alignments using secondary structure profiles. J. Mol. Biol. 313, 1003–1011 (2001)

    Article  CAS  PubMed  Google Scholar 

  47. Macke, T. J. et al. RNAMotif, an RNA secondary structure definition and search algorithm. Nucleic Acids Res. 29, 4724–4735 (2001)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Zhang, Y. et al. Model-based analysis of ChIP-seq (MACS). Genome Biol. 9, R137 (2008)

    Article  PubMed  PubMed Central  Google Scholar 

  49. Veldwijk, M. R. et al. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther. 6, 272–278 (2002)

    Article  CAS  PubMed  Google Scholar 

  50. Zuker, M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 31, 3406–3415 (2003)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


We thank E. Charpentier, I. Fonfara and K. Chylinski for discussions; A. Scherer-Hoock, B. Clear and the MIT Division of Comparative Medicine for assistance with animal experiments; Boston Children’s Hospital Viral Core and R. Xiao for assistance with AAV production; N. Crosetto for advice on BLESS; C.-Y. Lin and I. Slaymaker for experimental assistance; and the entire Zhang laboratory for support and advice. F.A.R. is a Junior Fellow at the Harvard Society of Fellows. W.X.Y. is supported by T32GM007753 from the National Institute of General Medical Sciences and a Paul and Daisy Soros Fellowship. J.S.G. is supported by a US Department of Energy Computational Science Graduate Fellowship. X.W. is a Howard Hughes Medical Institute International Student Research Fellow. P.A.S. is supported by United States Public Health Service grants RO1-GM34277, R01-CA133404 from the National Institutes of Health, and PO1-CA42063 from the National Cancer Institute, and partially by Cancer Center Support (core) grant P30-CA14051 from the National Cancer Institute. F.Z. is supported by the National Institutes of Health through NIMH (5DP1-MH100706) and NIDDK (5R01DK097768-03), a Waterman Award from the National Science Foundation, the Keck, New York Stem Cell, Damon Runyon, Searle Scholars, Merkin, and Vallee Foundations, and B. Metcalfe. F.Z. is a New York Stem Cell Foundation Robertson Investigator. The Children’s Hospital virus core is supported by an NIH core grant (5P30EY012196-17). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health. CRISPR reagents are available to the academic community through Addgene, and information about the protocols, plasmids, and reagents can be found at the Zhang laboratory website

Author information

Authors and Affiliations



F.A.R. and F.Z. conceived this study. F.A.R., L.C., W.X.Y. and F.Z. designed and performed the experiments with help from all authors. F.A.R., J.S.G., O.S., K.S.M., E.V.K. and F.Z. contributed to analysis of Cas9 orthologues, crRNA and tracrRNA, and PAM. A.J.K., F.A.R., X.W., and P.A.S. led ChIP and computational analysis and validation. F.A.R., W.X.Y. and L.C. performed BLESS and targeted sequencing of BLESS-identified off-target sites, and D.A.S. contributed computational analysis of BLESS data. W.X.Y., F.A.R., L.C. and B.Z. contributed animal data. W.X.Y., F.A.R., L.C., J.S.G., and F.Z. wrote the manuscript with help from all authors.

Corresponding author

Correspondence to Feng Zhang.

Ethics declarations

Competing interests

Patent applications have been filed as to the subject matter of the manuscript such as, for example, US patent 8,865,406 issued 21 October 2014 and US patent 8,895,308 issued 25 November 2014. F.Z. is a founder of Editas Medicine and scientific advisor for Editas Medicine and Horizon Discovery.

Extended data figures and tables

Extended Data Figure 1 Selection of Type II CRISPR-Cas loci from eight bacterial species.

a, Distribution of lengths for Cas9 > 600 Cas9 orthologues19. b, Schematic of Type II CRISPR-Cas loci and sgRNA from eight bacterial species. Spacer or ‘guide’ sequences are shown in blue, followed by direct repeats (grey). Predicted tracrRNAs are shown in red, and folded based on the Constraint Generation RNA folding model50.

Extended Data Figure 2 Cas9 orthologue cleavage pattern in vitro.

Stacked bar graph indicates the fraction of targets cleaved at 2, 3, 4, or 5 bp upstream of PAM for each Cas9 orthologue; most Cas9 enzymes cleave stereotypically at 3 bp upstream of PAM (red triangle).

Extended Data Figure 3 Test of Cas9 orthologue activity in 293FT cells.

a, SURVEYOR assays showing indel formation at human endogenous loci from co-transfection of Cas9 orthologues and sgRNA. PAM sequences for individual targets are shown above each lane, with the consensus region for each PAM highlighted in red. Red triangles indicate cleaved fragments. b, SaCas9 generates indels efficiently for a multiple targets. c, Box-whisker plot of indel formation as a function of SaCas9 guide length L, with unaltered guides (perfect match of L nucleotides, grey bars) or replacement of the 5′-most base of guide with guanine (G + L − 1 nucleotides, blue bars) (n = 8 guides).

Extended Data Figure 4 Optimization of SaCas9 sgRNA scaffold in mammalian cells.

a, Schematic of the Staphylococcus aureus subspecies aureus CRISPR locus. b, Schematic of SaCas9 sgRNA with 21-nucleotide guide, crRNA repeat (grey), tetraloop (black) and tracrRNA (red). The number of crRNA repeat to tracrRNA anti-repeat base-pairing is indicated above the grey boxes. SaCas9 cleaves targets with varying repeat:anti-repeat lengths in c, HEK 293FT and d, Hepa1-6 cell lines. (n = 3, error bars show s.e.m.)

Extended Data Figure 5 Genome-wide binding by Cas9-chromatin immunoprecipitation (dCas9-ChIP).

a, Unbiased identification of PAM motif for dSaCas9 and dSpCas9. Peaks were analysed for the best match by motif score to the guide region only within 50 nucleotides of the peak summit. The alignment was extended for 10 nucleotides at the 3′ end and visualized using Weblogo. Numbers in parentheses indicate the number of called peaks. b, Histograms show the distribution of the peak summit relative to motif for dSaCas9 and dSpCas9. Position 1 on x axis indicates the first base of PAM.

Extended Data Figure 6 Indel measurements at candidate off-target sites based on ChIP.

Indels at top off-target sites predicted by dCas9-ChIP for each Cas9 and sgRNA pair, based on ChIP peaks ranked by sequence similarity of the genomic loci to the guide motif (heat map in purple), or P value of ChIP enrichment over control (heat map in red). Lines connect the common targets (EMX1) and off-targets between the two Cas9 enzymes.

Extended Data Figure 7 Analysis pipeline of sequencing data from BLESS.

a, Overview of the data analysis pipeline starting from the raw sequencing reads. Representative sequencing read mappings and corresponding histograms of the pairwise distances between all the forward orientation (red) reads and reverse orientation (blue) reads, displayed for representative b, DSB hotspots and poorly defined DSB sites and c, Cas9-induced DSBs with detectable indels. Fraction of pairwise distances between reads overlapping by no more than 6 bp (dashed vertical line) are indicated over histogram plots.

Extended Data Figure 8 Indel measurements at off-target sites based on DSB scores.

List of top off-target sites ranked by DSB scores for each Cas9 and sgRNA pair. Indel levels are determined by targeted deep sequencing. Blue triangles indicate positions of peak BLESS signal, and where present, PAMs and targets with sequence homology to the guide are highlighted. Lines connect the common on-targets (EMX1) and off-targets between the two Cas9 enzymes. N.D., not determined.

Extended Data Figure 9 Indel measurements of top candidate off-target sites based on sequence similarity score.

Off-targets are predicted based on sequence similarity to on-target, accounting for number and position of Watson–Crick base-pairing mismatches as previously described22. NNGRR and NRG are used as potential PAMs for SaCas9 and SpCas9, respectively. Lines connect the common targets (EMX1) and off-targets between the two Cas9 enzymes. Correlation plots between indel percentages and b, prediction based on sequence similarity, c, ChIP peaks ranked by motif similarity, or d, DSB scores for top ranking off-target loci. Trendlines, r2, and P values are calculated using ordinary least squares.

Extended Data Figure 10 SaCas9 targeting Apob locus in the mouse liver.

a, Schematics illustrating the mouse Apob gene locus and the positions of the three guides tested. b, Experimental time course and c, SURVEYOR assay showing indel formation at target loci after intravenous injection of AAV2/8 carrying thyroxine-binding globulin (TBG) promoter-driven SaCas9 and U6-driven guide at 2 × 1011 total genome copies (n = 1 animal each). d, Oil-red staining of liver tissue from AAV- or saline-injected animals. Male C56BL/6 mice were injected at 8 weeks of age and analysed 4 weeks post injection.

Supplementary information

Supplementary Information

This file contains a Supplementary Discussion, Supplementary References, Supplementary Tables 1-9 and Supplementary Sequences. (PDF 769 kb)

PowerPoint slides

Source data

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ran, F., Cong, L., Yan, W. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing